About this trial
Genomic research has shown that a portion of leiomyosarcomas can be attributed to an underlying cancer predisposition syndrome. However, the optimal approach for incorporating germline testing into the care of these patients. This study is assessing the beliefs about the heritability of leiomyosarcoma and other cancer risks, and attitudes towards germline testing among leiomyosarcoma patients.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Actionable germline PV detected in the research context
Living
No prior germline testing for this PV
Able to speak and read English
Disqualifiers
None
Trial population
The study population will be Patients with a confirmed or suspected diagnosis of LMS and Relatives of LMS patients.
Trial design
Family-based
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Beliefs about the heritability of Leiomyosarcoma
This outcome will report the count of participants who self-reported a strong belief in heritability. Participants who responded on a questionnaire that sarcoma is somewhat or highly heritable are considered to have a strong belief in heritability. This outcome measure will be assessed on Day 1 of the study.
Secondary outcomes
Interest in germline genetic testing
This outcome will report the count of participants who self-reported an interest in germline genetic testing. This will report the number of participants who respond on a baseline questionnaire that they are interested in having a genetic test related to cancer risk.
Other outcomes
Uptake in germline genetic testing
This outcome will report the count of participants who proceed with germline genetic testing. Participants will be asked on their baseline questionnaire if they have completed germline genetic testing.
Preferences for receiving information about germline testing
This outcome will report the count of participants who self-reported sources for genetic testing information as helpful. Participants will rank questions about sources of information from "1 Not helpful at all" to "6 Extremely helpful" on their baseline questionnaire. Participants who reported \>5 on this scale are considered to have found the source for genetic testing information as helpful. This outcome will assess information presented in tables and graphs and information presented numerically.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Utah
Lead sponsor
National Cancer Institute (NCI)
Collaborator
University of New South Wales
Collaborator
University of Michigan
Collaborator